Drug Induced Liver Injury (DILI) presents a critical challenge to the pharmaceutical industry and patient care. The IQ DILI Initiative is an affiliate of the International Consortium for Innovation and Quality in Pharmaceutical Development focused on defining best practices for the detection, monitoring, management and prevention of DILI in clinical trials and post-marketing pharmacovigilance programs.